Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).
Standard
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). / Seidel, Christoph; Fenner, Martin; Länger, Florian; Bantel, Heike; Ganser, Arnold; Grünwald, Viktor.
In: BMC CANCER, Vol. 12, 2012, p. 186.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).
AU - Seidel, Christoph
AU - Fenner, Martin
AU - Länger, Florian
AU - Bantel, Heike
AU - Ganser, Arnold
AU - Grünwald, Viktor
PY - 2012
Y1 - 2012
N2 - The use of imatinib mesylate is associated with a progression free survival of 41?months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatinib treatment improves the recurrence-free survival in patients with GIST. Current recommendations include 1?year adjuvant treatment in GIST patients at risk but active studies explore different durations of treatment with an interval of up to 5?years. While the most frequent adverse events (AEs) are blood count alterations, abdominal discomfort and edema, the occurrence of grade 3 or 4 increase of AST or ALT is specified with 2.1% and 2.7% respectively.
AB - The use of imatinib mesylate is associated with a progression free survival of 41?months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatinib treatment improves the recurrence-free survival in patients with GIST. Current recommendations include 1?year adjuvant treatment in GIST patients at risk but active studies explore different durations of treatment with an interval of up to 5?years. While the most frequent adverse events (AEs) are blood count alterations, abdominal discomfort and edema, the occurrence of grade 3 or 4 increase of AST or ALT is specified with 2.1% and 2.7% respectively.
KW - Humans
KW - Male
KW - Middle Aged
KW - Magnetic Resonance Imaging
KW - Neoplasm Staging
KW - Pyrimidines/adverse effects/therapeutic use
KW - Antineoplastic Agents/adverse effects/therapeutic use
KW - Gastrointestinal Neoplasms/complications/diagnosis/drug therapy
KW - Liver Cirrhosis/chemically induced/diagnosis
KW - Piperazines/adverse effects/therapeutic use
KW - Protein Kinase Inhibitors/adverse effects/therapeutic use
KW - Humans
KW - Male
KW - Middle Aged
KW - Magnetic Resonance Imaging
KW - Neoplasm Staging
KW - Pyrimidines/adverse effects/therapeutic use
KW - Antineoplastic Agents/adverse effects/therapeutic use
KW - Gastrointestinal Neoplasms/complications/diagnosis/drug therapy
KW - Liver Cirrhosis/chemically induced/diagnosis
KW - Piperazines/adverse effects/therapeutic use
KW - Protein Kinase Inhibitors/adverse effects/therapeutic use
M3 - SCORING: Journal article
VL - 12
SP - 186
JO - BMC CANCER
JF - BMC CANCER
SN - 1471-2407
ER -
